Get to know our clinical trials

Clinical trial of TPX-0005 in patients with advanced solid tumors with ALK, ROS1 or NTRK1-3 rearrangements

THE AIM IS TO DETERMINE, MORE SPECIFICALLY, WHETHER REPOTRECTINIB WORKS, ESPECIALLY IN GROUPS OF PATIENTS WITH THE DIFFERENT TUMOR GENE REARRANGEMENTS.

Dr. Miguel Fernández de Sanmamed Gutiérrez Curriculum
Specialist Medical Oncology Department
Navarre headquarters
Cancer Center
Lung Cancer Area
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • FIRST-IN-HUMAN, MULTICENTER, OPEN-LABEL PHASE I/II STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF TPX-0005 IN PATIENTS WITH ADVANCED SOLID TUMORS WITH ALK, ROS1 OR NTRK1-3 REARRANGEMENTS (TRIDENT-1).
  • Code EudraCT: 2016-003616-13
  • Protocol number: TPX-0005-01
  • Promoter: Turning Point Therapeutics, Inc

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Read more about this clinical trial
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION